Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study. de Logeril M, Salen P, Martin J-L, Monjaud I, Delaye J, Mamelle N. Circulation 1999; 99: 779-85 
The first report of the Lyon Diet Heart Study appeared in 1994 after 2 years of the trial (de Logeril et al., Lancet 1994; 343: 1454-9) . The results were good. Some thought that they were too good to be true. The results at 46 months are now published and show that the initial promise has been fulfilled. The Lyon Diet Heart Study is a randomized, single-blind, secondary prevention trial to test the efficacy of a 'Mediterranean-type diet' compared to a 'prudent Western-type diet' following myocardial infarction. The 'Mediterraneantype diet' comprises pasta, fish, fruit and vegetables, and promotes intake of a-linolenic acid, an essential fatty acid present in only a few vegetable oils such as rapeseed oil and soya oil. Cardiac death and non-fatal myocardial infarction were reduced by 70% over 5 years in the experimental group compared with the control group. The improved event-free survival rates were evident almost from the start of the trial (compared with the 2-year lag period for lipid-lowering drugs).
Many physicians believe that it is easier to prescribe drugs than to change dietary habits. This trial shows that, with a little effort, most patients follow the advice given to them. What is more, the improved outcome was achieved without a change in conventional lipid profile, though plasma a-linolenic acid was significantly associated with improved prognosis. Vascular disease is so common in our society that those of us who have not yet had a myocardial infarction may consider adopting the 'Mediterranean-type diet' without waiting for the inevitable. Your grandmother may have told you that you are what you eat. Seems that she was right.
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Ann Clin Biochem 1999; 36: 537 -538 Comparison of serum concentrations of a-tocopherol and~-carotenein a cross sectional sample of obese and non-obese children (NHANESIll). Strauss RS. J Pediatr 1999; 134: 160-5 Relative antioxidant deficiency in obese children: a weighty contributor to morbidity? Lavine JE. J Pediatr 1999; 134: 132-3 About 25% of American children are officially overweight and are highly likely to become overweight adults. Adult obesity is associated with low serum concentrations of fat-soluble vitamins such as a-tocopherol and~-carotene in 4771 children aged between 6 and 19 years who were enrolled in the National Health and Examination Survey of America (NHANES III). 726 of the children were obese. Serum concentrations of a-tocopherol were corrected for lipid concentrations. Obese children did not differ from their normal-weight peers in dietary recall of intake of foods rich in a-tocopherol and~-carotene. Obese children were found to have markedly lower concentrations of these antioxidants regardless of sex, race and age.
Is this important? As Lavine discusses, low serum concentrations of antioxidants may be an indicator of oxidant stress, thought to be the mediator between obesity, diabetes, dyslipidaemia and cardiovascular disease. Oxidant stress may also be important in the development of liver disease. 13% of obese teenagers have raised serum activities of aminotransferases and a high prevalence of fatty, inflamed livers (non-alcoholic steatohepatitis) -the most common cause of chronic liver disease in North American teenagers. Steatosis persists even though serum activities of the aminotransferases are reduced by supplementing the diet with a-tocopherol. Both Strauss and Lavine conclude that the best way to lower future risk of cardiovascular and hepatic disease in children is to encourage a diet increased in fruit, vegetable and whole grain.
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Screening for ovarian cancer: a systematic review. Bell R, Petticrew M, Luengo S, Sheldon T A.
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Screening procedures for detection of ovarian cancer include ultrasound and analysis of the serum tumour marker CA125. The possible advantage of screening is a higher detection rate of localized (stage I) ovarian disease that is amenable to surgical intervention. Currently, three quarters of women are not diagnosed at stage I and the overall 5-year survival is 30%. However, for the 25% of women who are diagnosed at stage I the five year survival rate is 75%.
The two approaches to population screening in most common use are ultrasound alone (-100% sensitive in detecting disease) and CAI25 analysis followed by ultrasound if CAI25 is abnormal (-80% sensitive). The data for detection of stage 1 disease also suggest that ultrasound alone is more sensitive than CAl25/ultrasound (75% versus 50% detection rate) but these data have been collected in a number of diverse studies of largely selfselected women. Of concern, however, is evidence that the ultrasound-only approach has a lower specificity (false positive rate 1·2-2·5%) than the CAl25/ultrasound approach (false positive rate 0·1-0·6%) when used for population screening. This is mainly due to ultrasound's higher detection rate of tumours of borderline malignancy for which intervention would not normally be required. This higher false positive rate may lead to recall of substantial numbers of women who are free of disease.
The cost benefit of population screening with either approach is as yet unknown. Ovarian cancer is the seventh most common cancer in women worldwide but the incidence is relatively low at approximately 19·7 women per 100000 (in the UK); thus, screening is associated with a low positive predictive value and hence may confer limited overall cost benefit. Ultrasound is typically carried out every I to 3 years (compared with annually for CA125) but there is currently no evidence to indicate what is best practice. On the basis of annual CAl25-based screening, modelling studies suggest that, although this approach may well be more cost effective than annual ultrasound screening, it would probably be less beneficial.
For the clinical scientist, there is potential for involvement in a number of areas of new investigation. There is some evidence accumulating that the tumour markers OVX-l and M-CSF, when measured alongside CA125, may improve its sensitivity without compromising specificity, but improved laboratory performance of both these newer assays is required. Other assays such as lipid-associated sialic acid (LASA), NB/70K, H-neu and urinary gonadotropin need further investigation. The use of algorithms to assess optimal combinations of tests, algorithms that determine threshold intervention levels for ultrasound/surgery and algorithms that relate rate of change of tumour markers to disease detection also warrant further evaluation. Genetic testing in a diagnostic laboratory setting is likely to become viable for the small number of women with a familial predisposition to ovarian cancer. A number of cancer predisposition genes such as the BRCA I and BRCA2 breast-ovarian cancer tumour suppressor genes have been identified through genetic linkage studies, and identification of the mutations in these genes to assess disease risk is a field of growing interest.
